LLY

834.19

+4.45%↑

UNH

616.78

+1.88%↑

JNJ

155.63

-0.71%↓

NVO

107.22

-0.35%↓

ABBV

199.85

-0.38%↓

LLY

834.19

+4.45%↑

UNH

616.78

+1.88%↑

JNJ

155.63

-0.71%↓

NVO

107.22

-0.35%↓

ABBV

199.85

-0.38%↓

LLY

834.19

+4.45%↑

UNH

616.78

+1.88%↑

JNJ

155.63

-0.71%↓

NVO

107.22

-0.35%↓

ABBV

199.85

-0.38%↓

LLY

834.19

+4.45%↑

UNH

616.78

+1.88%↑

JNJ

155.63

-0.71%↓

NVO

107.22

-0.35%↓

ABBV

199.85

-0.38%↓

LLY

834.19

+4.45%↑

UNH

616.78

+1.88%↑

JNJ

155.63

-0.71%↓

NVO

107.22

-0.35%↓

ABBV

199.85

-0.38%↓

Search

Bristol-Myers Squibb Co.

Geschlossen

Branche Gesundheitswesen

54.14 -1.1

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

53.97

Max

54.26

Schlüsselkennzahlen

By Trading Economics

Einkommen

-469M

1.2B

Verkäufe

-300M

12B

KGV

Branchendurchschnitt

14.05

104.138

EPS

1.8

Dividendenrendite

4.639

Gewinnspanne

10.176

Angestellte

34,100

EBITDA

13B

4.4B

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

-0.26 downside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

4.64%

1.72%

Nächstes Ergebnis

6. Feb. 2025

Nächste Dividendenausschüttung

30. Jan. 2025

Nächstes Ex-Dividendendatum

2. Jan. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-527M

111B

Vorheriger Eröffnungskurs

55.24

Vorheriger Schlusskurs

54.14

Nachrichtenstimmung

By Acuity

36%

64%

110 / 391 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Bristol-Myers Squibb Co. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

31. Okt. 2024, 11:40 UTC

Ergebnisse

Bristol-Myers Lifts 2024 Outlook After 3Q Sales Climb

28. Okt. 2024, 22:40 UTC

Ergebnisse

Correction to Bristol-Myers Squibb 2024 Guidance Headline on July 26

30. Sept. 2024, 13:06 UTC

Wichtige Markttreiber

Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb

26. Juli 2024, 14:08 UTC

Ergebnisse

Trending: Bristol Myers Squibb 2Q Adjusted EPS Beat Expectations

31. Okt. 2024, 20:13 UTC

Ergebnisse

Bristol Myers Screams To A Year-High After Walloping Profit Expectations -- IBD

31. Okt. 2024, 12:15 UTC

Top News
Ergebnisse

Bristol Myers Stock Rises. The Drugmaker Hiked Guidance After Sales Beat. -- Barrons.com

31. Okt. 2024, 11:40 UTC

Top News
Ergebnisse

Bristol Myers Stock Rises After Earnings Beat, Guidance Hike -- Barrons.com

31. Okt. 2024, 11:13 UTC

Ergebnisse

Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance -- IBD

31. Okt. 2024, 11:10 UTC

Ergebnisse

Bristol Myers Earnings Top Estimates And Company Raises Guidance -- MarketWatch

31. Okt. 2024, 11:03 UTC

Ergebnisse

Bristol-Myers Squibb Raises FY24 View To Adj EPS 75c-Adj EPS 95c >BMY

31. Okt. 2024, 11:02 UTC

Ergebnisse

Bristol-Myers Squibb Raising 2024 Rev Guidance to About +5% (+6% Adjusting for Foreign Exchange) >BMY

31. Okt. 2024, 10:59 UTC

Ergebnisse

Bristol-Myers Squibb 3Q Adj EPS $1.80 >BMY

31. Okt. 2024, 10:59 UTC

Ergebnisse

Bristol-Myers Squibb 3Q Net $1.2B >BMY

31. Okt. 2024, 10:59 UTC

Ergebnisse

Bristol-Myers Squibb 3Q Rev $11.9B >BMY

31. Okt. 2024, 10:59 UTC

Ergebnisse

Bristol-Myers Squibb 3Q EPS 60c >BMY

31. Okt. 2024, 10:59 UTC

Ergebnisse

Bristol-Myers Squibb 3Q Gross Margin 75.1% >BMY

26. Okt. 2024, 11:00 UTC

Top News

Heard on the Street: Pfizer's Activist Battle Might Fizzle -- but Its Stock Probably Won't -- WSJ

7. Okt. 2024, 14:16 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Pfizer Stock Rises After It Gets an Activist. What Starboard's Track Record With Pharma Tells Us. -- Barrons.com

7. Okt. 2024, 13:45 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Pfizer Stock Rises After It Gets an Activist. What Starboard's Track Record With Pharma Tells Us. -- Barrons.com

7. Okt. 2024, 11:54 UTC

Top News

Pfizer Gets an Activist. What Starboard's Track Record With Pharma Tells Us. -- Barrons.com

7. Okt. 2024, 09:30 UTC

Top News

Old Drug Repurposed for Schizophrenia Could Reap Alzheimer's Windfall -- Heard on the Street -- WSJ

27. Sept. 2024, 18:36 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More -- Barrons.com

27. Sept. 2024, 09:15 UTC

Heiße Aktien

Stocks to Watch Friday: Bristol Myers Squibb, EchoStar, Costco -- WSJ

26. Sept. 2024, 23:20 UTC

Top News

First Novel Schizophrenia Treatment in Decades Gains FDA Approval -- Update

26. Sept. 2024, 22:56 UTC

Top News

First Novel Schizophrenia Treatment in Decades Gains FDA Approval -- WSJ

16. Aug. 2024, 11:30 UTC

Top News

The Feds Are 'Playing Nice' With Pharma, at Least for Now -- Heard on the Street -- WSJ

8. Aug. 2024, 10:30 UTC

Top News

Big Pharma Cuts R&D, Sending Shudders Through Industry -- Heard on the Street -- WSJ

29. Juli 2024, 10:30 UTC

Top News

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

26. Juli 2024, 14:51 UTC

Ergebnisse

Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win -- IBD

26. Juli 2024, 13:53 UTC

Ergebnisse

Trending: Bristol Myers Squibb 2Q Adj EPS Beat Expectations

Peer-Vergleich

Kursveränderung

Bristol-Myers Squibb Co. Prognose

Kursziel

By TipRanks

-0.26% Nachteil

12-Monats-Prognose

Durchschnitt 54 USD  -0.26%

Hoch 64 USD

Tief 36 USD

Basierend auf 15 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Bristol-Myers Squibb Co. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

15 ratings

3

Buy

10

Halten

2

Sell

Technischer Score

By Trading Central

52.64 / 55.9Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

110 / 391 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.